# Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

> **NCT06550011** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Avirmax Biopharma Inc** · enrollment: 18 (estimated)

## Conditions studied

- Neovascular (Wet) AMD

## Interventions

- **DRUG:** ABI-110 Low Dose
- **DRUG:** ABI-110 Medium Dose
- **DRUG:** ABI-110 High Dose

## Key facts

- **NCT ID:** NCT06550011
- **Lead sponsor:** Avirmax Biopharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2027-01-13
- **Final completion:** 2031-01-16
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550011, "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06550011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*